Clinical Trial: RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

---

Official Title: Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid

Brief Summary:

• According to Martin F et al, AKT is highly phosphorylated in phenochromocytoma but not in benign adrenocortical tumors.
• In nonfunctioning carcinoid, the PI3K/AKT/mTOR pathway is activated.
• Although mTOR is clearly an attractive therapeutic target in tumor, no clinical study on mTOR inhibition by RAD001 have been conducted in pheochromocytoma or extra-adrenal paraganglioma or non-functioning carcinoid.
• So we design this phase II study of RAD001 in pheochromocytoma or extra-adrenal paraganglioma or non-functioning carcinoid to evaluate the efficacy of RAD001 in this orphan disease.